AstraZeneca Grows US Cell Therapy Production Capacity
AstraZeneca has announced a $300 million investment in a new state-of-the-art facility in Rockville, Maryland, aimed at advancing its...
ICON Survey Stresses Combo Therapies in Obesity Care
ICON plc conducted an industry survey of over 100 professionals engaged in obesity-related clinical research, revealing expectations for the...
Gilead Evoke-01 Phase 3 Study: Critical Update Issued
Gilead Sciences, Inc. announced that the Phase 3 EVOKE-01 study, which evaluated Trodelvy® (sacituzumab govitecan-hziy; SG) against docetaxel in...
8-Year Data: BMS Opdivo & Yervoy Outperform in RCC Survival
Bristol Myers Squibb (BMS) announced that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) continues to show significant long-term...
Opdivo & Cabometyx Show 4-Year Benefits in RCC Trial
Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) has shown continued benefits in the first-line treatment of advanced renal cell...
Arcus & Gilead: Quemliclustat Regimens Show Hope in Pancreatic Cancer
Arcus Biosciences, Inc. announced promising overall survival data from the ARC-8 Phase 1b trial, co-developed with Gilead Sciences. The...
Takeda’s HYQVIA Wins FDA Approval for CIDP Therapy
Takeda has announced that the FDA has approved HYQVIA® for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as...
Dubai’s Arab Health: Leading New Medical Advances
Join us at the Arab Health 2024 conference, set in the vibrant city of Dubai, from January 29 to...
FDA Nods Merck’s Keytruda for Stage III-IVA Cervical Cancer
Merck announced that the FDA has approved KEYTRUDA, their anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for treating patients...
Pfizer Tivdak SLA Accepted by FDA for Priority Cervical Cancer Review
Genmab A/S and Pfizer Inc. announced the FDA’s acceptance of the supplemental Biologics License Application (sBLA) to potentially convert...